Dasatinib - Prometheus IP

According to a recent Reuters report, two Indian generic drug manufacturers - BDR Pharma and Lee Pharma have decided to give up on pursuing their compulsory license applications rejected by the Indian patent office “blaming a lack of government support for cheap generics and pressure from Big Pharma”.

India’s compulsory licensing policy, though TRIPS compliant, has come under scathing attack from many quarters of developed countries, mainly attributed to the pressure from big pharma lobbies based in those countries. India granted its first compulsory license in Mar 2012 to NATCO Pharma Ltd., a generic drug manufacturer, to produce Nexaver, an anticancer drug patented...